No More Sleepless Nights — A Neurologist’s Review

Peter Hauri, PhD & Shirley Linde, PhD · Wiley · Updated through 1996

Dimension-by-Dimension Assessment

Dimension	Rating	Comment
General insomnia guidance	★★★★☆	CBT-I framework remains the standard of care
Applicability to ε4 carriers	★★☆☆☆	Critical mechanisms (glymphatic, circadian–Aβ link) postdate the book
OSA guidance	★★★☆☆	Discussed but ε4-specific compounding effects are absent
Pharmacological guidance	★★★☆☆	SWS-suppression risk of sedative-hypnotics not addressed
Overall	3.5 / 5	Essential historical foundation; must be read alongside current neuroscience

No More Sleepless Nights (Peter Hauri, PhD, and Shirley Linde, PhD; Wiley, updated editions through 1996) remains one of the most cited popular sleep medicine texts of the late 20th century. Hauri, a founder of the Mayo Clinic Sleep Disorders Center and a principal architect of modern cognitive-behavioral therapy for insomnia (CBT-I), produced a foundational guide covering sleep hygiene, stimulus control, sleep restriction therapy, relaxation techniques, and pharmacological considerations. The book is accessible, pragmatic, and grounded in the clinical sleep science of its era.

It earns a 4/5 rating for general audiences. However, for APOE ε4 carriers, the stakes of implementing this book’s guidance — and the limitations of what it omits — have taken on a dimension that Hauri could not have anticipated in 1990. The intervening three decades of neuroscience have fundamentally transformed how we must think about sleep in this population.

The Glymphatic System and Amyloid-β Clearance

The discovery of the glymphatic system (Iliff et al., Science Translational Medicine, 2012) provided the neurobiological framework for understanding why sleep architecture — specifically slow-wave sleep (SWS) — matters in a way that is mechanistically distinct for individuals at genetic risk for Alzheimer’s disease. The glymphatic system is a cerebrospinal fluid–interstitial fluid exchange network driven by aquaporin-4 (AQP4) water channels on astrocytic endfeet, responsible for clearance of amyloid-β (Aβ) and tau from the brain parenchyma. This system operates predominantly during SWS — the very phase most vulnerable to disruption across the lifespan.

Critically, the APOE ε4 allele directly disrupts meningeal lymphatic function, increasing AD risk through deficits in Aβ clearance (Ding et al., Alzheimers Dement. 2025). The ε4 carrier already faces impaired glymphatic efficiency at baseline; sleep disruption compounds this deficit synergistically.

APOE ε4 and Sleep Disruption: A Synergistic Interaction

The most compelling mechanistic data come from the Holtzman laboratory at Washington University. Using APPPS1 mice expressing human APOE-ε3 or APOE-ε4, chronic sleep deprivation significantly increased Aβ deposition and peri-plaque neuritic plaque-tau (NP-tau) pathology in the presence of APOE4 — but not APOE3. Sleep deprivation also significantly decreased microglial clustering around plaques and AQP4 polarization around blood vessels in the presence of APOE4, but not APOE3 (Wang et al., J Clin Invest. 2023).

Circadian Rhythm Fragmentation and Amyloid PET Burden

The Rotterdam Study (Nguyen Ho et al., JAMA Neurology, 2024) provides critical human-level evidence. In a cohort study using 7-day actigraphy and amyloid-β PET at follow-up (mean 7.8 years), higher intradaily variability — an objective measure of fragmented 24-hour activity rhythms — was associated with greater subsequent Aβ PET burden. The APOE ε4 genotype powerfully modified this association, with the effect substantially stronger in APOE4 carriers compared to noncarriers.

Crucially, findings held after excluding participants with existing AD pathology at baseline — suggesting that fragmented rest-activity rhythms may precede Aβ deposition rather than simply accompany it. This temporal directionality elevates the clinical urgency considerably.

Sleep EEG Biomarkers: The Sleep Spindle Problem

Fast-frequency sleep spindles (13–16 Hz), generated by the thalamic reticular nucleus during NREM Stage 2 sleep, are critical to overnight memory consolidation. In APOE ε4 carriers, these spindles are compromised before any clinical symptom appears. In cognitively unimpaired, amyloid-negative older adults enriched with parental history of AD and APOE ε4 positivity, glial activation was associated with prefrontal fast-frequency sleep spindle deficits. Serial mediation models detected indirect effects through microglial activation markers, then tau phosphorylation and synaptic degeneration markers (Mander et al., Sleep, 2022).

This pathway — neuroinflammation → tau phosphorylation → spindle loss → memory impairment — operates prior to amyloid positivity, suggesting that sleep EEG may become an early biomarker of neurodegenerative risk. Confirmatory data from Wei et al. (Science Bulletin, 2025) demonstrate progressive slow oscillation–spindle coupling disruption from cognitively normal to MCI to AD dementia, with APOE ε4 and elevated amyloid and tau burden independently associated with this disruption — and with the disruption predicting accelerated cognitive decline at two-year follow-up.

Synergistic Effect on Plasma Biomarkers

In the SILCODE cohort (972 participants), individuals with both high-risk sleep profiles and APOE ε4 positivity had higher plasma neurofilament light chain (NfL) levels and a higher risk of dementia than those with normal sleep without ε4. NfL elevation mediated approximately 23% of the relationship between sleep disorder severity and cognitive impairment — implicating a neurodegeneration-linked mechanism, not simply psychological distress (Yu et al., CNS Neurosci Ther. 2024).

Sleep Hygiene and Stimulus Control

Hauri’s first-line recommendations — consistent wake times, eliminating the bedroom as a workspace, restricting time in bed to actual sleep time — map directly onto what we now understand as circadian entrainment and arousal-threshold management. For APOE ε4 carriers, circadian consistency is not cosmetic. The Rotterdam Study data confirm that fragmentation of the 24-hour activity rhythm is the variable most strongly associated with Aβ accumulation in ε4 carriers. Hauri’s emphasis on consolidating sleep into a consistent block directly addresses this fragmentation risk.

Sleep Restriction Therapy

This is arguably the most evidence-based intervention in the book and the core of modern CBT-I. Temporarily restricting time in bed to actual sleep time, building sleep pressure and consolidating fragmented sleep, is mechanistically sound and particularly valuable for ε4 carriers whose slow-wave sleep is likely disproportionately affected by fragmentation. There is no equivalent pharmacological intervention that reliably restores SWS architecture.

The Warning About Sedative-Hypnotic Medications

Hauri appropriately cautions against long-term benzodiazepine and sedative-hypnotic use for insomnia. For ε4 carriers, this warning carries heightened urgency: benzodiazepines and Z-drugs (zolpidem, eszopiclone) suppress slow-wave sleep — the precise sleep stage during which glymphatic clearance of Aβ peaks. Achieving sedation while suppressing SWS may worsen net Aβ clearance even while subjectively improving sleep. Clinicians advising ε4 carriers must communicate this explicitly.

Glymphatic Biology Is Absent

Published before the discovery of the glymphatic system, the book has no framework for understanding why sleep architecture specifically matters for those at genetic risk for AD. Hauri frames poor sleep as impairing daytime function; the current literature frames poor sleep in ε4 carriers as potentially accelerating amyloid plaque deposition and tau seeding decades before symptom onset.

Obstructive Sleep Apnea Requires Special Attention

Hauri addresses OSA, but the ε4-specific compounding deserves emphasis the book does not provide. APOE ε4 carriers with untreated OSA face three concurrent pathological mechanisms: (1) baseline impaired glymphatic clearance from ε4 biology; (2) SWS suppression from arousal-driven fragmentation; and (3) episodic hypoxemia promoting neuroinflammation. Evaluation and aggressive treatment of OSA should be a priority intervention in this population.

Sleep Spindle Deficits Cannot Be Fully Addressed by Behavioral Means Alone

Emerging literature suggests APOE ε4 carriers may have intrinsic NREM slow-wave and spindle deficits that precede both clinical symptoms and amyloid positivity. Behavioral interventions can consolidate and protect sleep architecture but are unlikely to fully restore thalamocortical spindle generation compromised by neuroinflammation and early tau pathology. The behavioral toolkit is necessary — but may be insufficient as a standalone strategy.

The following represent clinical priorities informed by current peer-reviewed evidence.

Study / Finding	Journal · Year	Study Type	Evidence Grade
APOE4 + SD → ↑ Aβ deposition, ↑ NP-tau, ↓ AQP4 polarization (Wang et al.)	J Clin Invest. 2023	Preclinical (mouse model)	Grade B
Fragmented 24-hr rhythms → ↑ Aβ PET burden, stronger in APOE4 carriers (Nguyen Ho et al.)	JAMA Neurol. 2024	Prospective cohort (Rotterdam Study)	Grade A
Sleep+/APOE4+ → ↑ plasma NfL, ↑ dementia risk (Yu et al.)	CNS Neurosci Ther. 2024	Prospective cohort (SILCODE, n=972)	Grade A
SO-spindle coupling disruption → cognitive decline; APOE4 associated (Wei et al.)	Sci Bull. 2025	Cross-sectional + 2-yr longitudinal (n=93)	Grade B
Sleep spindle deficits linked to neuroinflammation, tau, and memory — pre-amyloid (Mander et al.)	Sleep 2022	Cross-sectional observational (n=58)	Grade B
APOE4 disrupts meningeal lymphatics → Aβ clearance deficits (Ding et al.)	Alzheimers Dement. 2025	Mechanistic review	Grade C